SH3GLB1 and neoplasm: As part of his inclusion in the DKTK MASTER Trial (NCT05852522), the patient had received a first tumor DNA and RNA NGS analysis with identification of a FGFR2-SH3GLB1 fusion, likely presenting the main tumor driver.